Physician profile
Japeth Durham
NPI 1144556341
$2,807.82
in general payments reported to CMS, 2019-2025
26 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $537 · 2024: $719 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $350.67 | 2023-2025 | Repatha, Repatha |
| Pfizer INC. | $344.12 | 2023-2025 | |
| Abbott Laboratories | $317.87 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Triclip |
| Novartis Pharmaceuticals Corporation | $245.49 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.74 | 2024-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $147.22 | 2022-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $121.00 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $120.99 | 2024-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $115.82 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $105.69 | 2024 | Arcalyst |
| Philips North America LLC | $101.11 | 2024-2025 | Ecc Solutions, Extended Holter, Mcot |
| Astrazeneca Pharmaceuticals LP | $96.78 | 2023-2025 | Farxiga, Lokelma |
| Irhythm Technologies, INC. | $92.62 | 2024 | Zio Xt Patch, Zio Monitor |
| Novo Nordisk INC | $92.08 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $81.11 | 2025 | Onpattro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.34 | 2023-2025 | Jardiance |
| Boston Scientific Corporation | $54.73 | 2024-2025 | Bodyguardian |
| Bridgebio Pharma, INC. | $48.13 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $24.96 | 2024 | Uptravi, Opsumit |
| Cvrx, INC. | $23.55 | 2023 | Barostim Neo System |
| Glaxosmithkline, LLC. | $22.95 | 2025 | Arexvy, Shingrix |
| Terumo Medical Corporation | $22.04 | 2025 | Angio-Seal |
| Vital Connect, INC | $21.88 | 2023 | Vitalpatch Rtm |
| Esperion Therapeutics, INC. | $15.68 | 2025 | Nexletol |
| Scpharmaceuticals INC. | $15.26 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Japeth Durham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.